First-Line Treatment Regimen for Drug-Susceptible Tuberculosis
Ethambutol remains included in the first-line regimen for drug-susceptible pulmonary tuberculosis in current international and US guidance. [1,2]
Core Recommendation
- The US ATS/CDC/ERS/IDSA update recommends a drug-susceptible regimen in which ethambutol is included during the initial intensive phase for pediatric non-severe pulmonary TB (2HRZE/2HR). [1]
- WHO guidance for drug-susceptible TB continues to define the standard 6-month regimen as 2 months of isoniazid, rifampicin, pyrazinamide, and ethambutol, followed by 4 months of isoniazid and rifampicin (2HRZE/4HR). [2]
Medication Selection Algorithm
- Standard drug-susceptible TB intensive phase includes four first-line agents: isoniazid, rifampicin, pyrazinamide, and ethambutol. [2]
- Alternative shorter all-oral regimens may replace ethambutol in some WHO options, but the standard regimen includes ethambutol in the intensive phase. [2]
Monotherapy Versus Combination Therapy
- Drug-susceptible TB treatment should be delivered as multi-drug combination therapy using the recommended regimen composition. [1,2]
Initiation Thresholds
- Regimen selection is based on drug-susceptibility results confirming drug-susceptible tuberculosis. [1,2]
Common Pitfalls to Avoid
- Omitting ethambutol from regimens that are specified to include it during the intensive phase conflicts with standard drug-susceptible regimen definitions in major guidance documents. [1,2]
Treatment Goal
- The treatment goal for drug-susceptible TB is cure using the guideline-recommended regimen composition for the applicable patient group. [1,2]